Despite a near-total lack of evidence that BPC 157 is effective or even safe for use in humans, this peptide is being touted for use to repair muscle, tendon and ligament damage in athletes, for recovery from surgery, and to improve gut health, amongst other indications
View Study [3]"Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity" Garvey WT et al., 2025 Finding: The REDEFINE 1 Phase 3 trial showed CagriSema achieved 20.4% weight loss versus 3% with placebo over 68 weeks in 3,417 participants
High Arg1 expression is associated with M2 polarization and exerts immunosuppressive effects, whereas low IDO1 expression is closely associated with loss of tolerance and enhanced pro-inflammatory responses (84)
The peptide repairs intestinal mucosal damage, restores tight junction integrity (addressing leaky gut), normalizes gastric emptying and intestinal motility, and protects against NSAID-induced ulcers